Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ekaterina Manuilova

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 17, 2025
Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSFEkaterina Manuilova, Isabelle Schrurs, Sandra Rutz, et al.
Clinical Chemistry and Laboratory Medicine|November 19, 2013
NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunctionLeon Holzscheiter, Claus Beck, Sandra Rutz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 23, 2022
Clinical performance and robustness evaluation of plasma amyloid-β<sub>42/40</sub> prescreeningChristina Rabe, Tobias Bittner, Alexander Jethwa, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 23, 2020
Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSFOskar Hansson, Sandra Rutz, Henrik Zetterberg, et al.
Plos One|December 17, 2015
Comparison of Plasma and Urine Biomarker Performance in Acute Kidney InjuryGunnar Schley, Carmen Köberle, Ekaterina Manuilova, et al.
Clinical Chemistry and Laboratory Medicine|October 25, 2022
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's diseaseKaj Blennow, Erik Stomrud, Henrik Zetterberg, et al.
Clinical Biochemistry|May 27, 2019
Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MSLeslie M Shaw, Oskar Hansson, Ekaterina Manuilova, et al.
Clinical Chemistry and Laboratory Medicine|March 11, 2025
Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer's disease assessment: findings from the Apollo studyHenrik Schinke, Magnus Förnvik Jonsson, Mayme Gummesson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2025
Blood-based pre-screening in the SKYLINE secondary prevention Ph3 gantenerumab studyAlina Bauer, Christina Rabe, Courtney Schiffman, et al.
Alzheimer'S Research & Therapy|April 3, 2020
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imagingJames D Doecke, Larry Ward, Samantha C Burnham, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 17, 2025
Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSFEkaterina Manuilova, Isabelle Schrurs, Sandra Rutz, et al.
Clinical Chemistry and Laboratory Medicine|November 19, 2013
NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunctionLeon Holzscheiter, Claus Beck, Sandra Rutz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 23, 2022
Clinical performance and robustness evaluation of plasma amyloid-β<sub>42/40</sub> prescreeningChristina Rabe, Tobias Bittner, Alexander Jethwa, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 23, 2020
Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSFOskar Hansson, Sandra Rutz, Henrik Zetterberg, et al.
Plos One|December 17, 2015
Comparison of Plasma and Urine Biomarker Performance in Acute Kidney InjuryGunnar Schley, Carmen Köberle, Ekaterina Manuilova, et al.
Clinical Chemistry and Laboratory Medicine|October 25, 2022
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's diseaseKaj Blennow, Erik Stomrud, Henrik Zetterberg, et al.
Clinical Biochemistry|May 27, 2019
Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MSLeslie M Shaw, Oskar Hansson, Ekaterina Manuilova, et al.
Clinical Chemistry and Laboratory Medicine|March 11, 2025
Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer's disease assessment: findings from the Apollo studyHenrik Schinke, Magnus Förnvik Jonsson, Mayme Gummesson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2025
Blood-based pre-screening in the SKYLINE secondary prevention Ph3 gantenerumab studyAlina Bauer, Christina Rabe, Courtney Schiffman, et al.
Alzheimer'S Research & Therapy|April 3, 2020
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imagingJames D Doecke, Larry Ward, Samantha C Burnham, et al.
Pageof 2